EGFR (Epidermal Growth Factor Receptor)

Hatil A. C., Çiçek E., Oyken M., Erson-Bensan A. E.

Atlas of Genetics and Cytogenetics in Oncology and Haematology, cilt.24, sa.9, ss.325-332, 2020 (Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 9
  • Basım Tarihi: 2020
  • Doi Numarası: 10.4267/2042/70782
  • Dergi Adı: Atlas of Genetics and Cytogenetics in Oncology and Haematology
  • Derginin Tarandığı İndeksler: Scopus, EMBASE
  • Sayfa Sayıları: ss.325-332
  • Anahtar Kelimeler: anti-EGFR, panitumumab, childhood, colorectal cancer, OVARIAN METASTASES, YOUNG-ADULTS, CARCINOMA, ADOLESCENTS, CHILDREN, CHEMOTHERAPY, BEVACIZUMAB, CHILDHOOD, SURVIVAL, HEREDITARY
  • Orta Doğu Teknik Üniversitesi Adresli: Evet

Özet

© 2020 Atlas of Genetics and Cytogenetics in Oncology and Haematology.ERBB family member epidermal receptor tyrosine kinase (EGFR) is composed of 28 exons and 27 introns. EGFR codes for 11 transcripts and 8 of them are protein coding. EGFR is a transmembrane glycoprotein that can be activated by several different ligands such as epidermal growth factor (EGF), transforming growth factor-alpha (TGFA), heparin-binding EGF-like growth factor (HBEGF), betacellulin (BTC), amphiregulin (AREG), epiregulin (EREG), and epigen (EPGN) (Singh, 2016). Ligand binding induces the dimerization of EGFR and autophosphorylation followed by a cascade of downstream phosphorylation events (Capuani et al., 2015). EGFR activation plays a key role in cell survival, proliferation, migration and differentiation (Purba, 2017).